Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic extends Activa therapy to dystonia:

This article was originally published in Clinica

Executive Summary

Medtronic has gained US approval to expand the use of its Activa brain stimulation technology to the treatment of a neurological movement disorder called dystonia. The device, approved under the agency's Humanitarian Device Exemption regulations for treating the most severe and disabling forms of the condition, is already cleared for treating symptoms of advanced Parkinson's disease and essential tremor. Medtronic says that every year in the US around 2,400 patients are diagnosed with forms of dystonia that may be treated with the Activa device. European approval for the dystonia indication is expected to come later this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel